PMID- 16722329
OWN - NLM
STAT- MEDLINE
DCOM- 20060717
LR  - 20161020
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 27
IP  - 2 Suppl 1
DP  - 2006 Mar-Apr
TI  - Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with 
      anti-immunoglobulin E antibody.
PG  - S29-32
AB  - Allergic diseases of the airways, including asthma and allergic rhinitis, remain 
      highly prevalent with associated symptoms placing considerable restrictions on 
      the physical, emotional, and social functioning of the affected individual. It is 
      now recognized that immunoglobulin E (IgE) plays a central role in mediating the 
      allergic response that follows exposure to allergens after an initial process of 
      sensitization. This sensitization process results in the overproduction of 
      antigen-specific IgE. Omalizumab, a recombinant humanized monoclonal antibody, is 
      the first therapeutic agent specifically targeting IgE. It has been investigated 
      extensively in the treatment of patients with allergic diseases and is approved 
      in the United States only for the treatment of patients with moderate-to-severe 
      persistent asthma. Although not currently approved by the Food and Drug 
      Administration for this specific indication, omalizumab also has been shown to be 
      effective in patients with seasonal and perennial allergic rhinitis. As expected 
      with a systemic anti-IgE agent, omalizumab also has been found to be helpful in 
      the treatment of patients with concomitant asthma and allergic rhinitis. The 
      efficacy of omalizumab in a range of allergic diseases reaffirms the importance 
      of IgE in the pathogenesis of these conditions and shows the potential benefit to 
      be obtained by inhibiting IgE, especially in patients with more severe and 
      comorbid allergic diseases.
FAU - Berger, William E
AU  - Berger WE
AD  - Mission Viejo Medical Center, Mission Viejo, California 92691, USA. 
      weberger@uci.edu
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Antibodies, Anti-Idiotypic/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hypersensitivity, Immediate/diagnosis/*drug therapy
MH  - Male
MH  - Omalizumab
MH  - Prognosis
MH  - Rhinitis, Allergic, Perennial/diagnosis/*drug therapy
MH  - Risk Assessment
MH  - Treatment Outcome
RF  - 36
EDAT- 2006/05/26 09:00
MHDA- 2006/07/18 09:00
CRDT- 2006/05/26 09:00
PHST- 2006/05/26 09:00 [pubmed]
PHST- 2006/07/18 09:00 [medline]
PHST- 2006/05/26 09:00 [entrez]
PST - ppublish
SO  - Allergy Asthma Proc. 2006 Mar-Apr;27(2 Suppl 1):S29-32.